Skip to main content
Premium Trial:

Request an Annual Quote

UNT Science Center Evaluating Abbott's mtDNA ID Platform

NEW YORK (GenomeWeb News) – Abbott and the University of North Texas Science Center have entered into a collaboration to evaluate Abbott's Plex-ID system for the identification of human remains.

Under a collaborative research agreement announced today, Abbott has installed a Plex-ID analyzer at UNT Health Science Center and is supplying the Plex-ID mtDNA assay for characterizing mitochondrial DNA from aged or degraded biological specimens. The platform will be used to identify human remains in missing persons or human trafficking cases, Abbott said.

The Plex-ID system, which was launched in 2011, can run mtDNA and nuclear DNA forensics assays in a single, fully automated run, and combines PCR and high precision electrospray ionization mass spectrometry to establish and compare the base mtDNA profile from biological specimens.

"Working with the UNT Health Science Center is a major step toward establishing Plex-ID as a system of choice for DNA testing in forensics laboratories," Steven Hofstadler, divisional vice president of R&D for Abbott's Ibis Biosciences subsidiary, said in a statement.

UNT Health Science Center identifies a large percentage of human remains found in the US each year, Abbott said.

Terms of the agreement were not disclosed.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.